longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

ESYN

ESYN
----

LongbridgeAI

Uranium Royalty’s Sweetwater Deal Outshines a Wave of Micro-Cap Reverse Splits

Global Report
Sep 25, 2026 at 10:11 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

While Uranium Royalty rides a massive acquisition to record profits, smaller players like Chanson and EZGO are leaning on reverse splits and strategic pivots to stay afloat.

The micro-cap space is seeing a flurry of financial engineering as companies fight to maintain compliance and scale. Leading the news cycle is Uranium Royalty Corp. (UUUG.US), which recently closed its milestone Sweetwater transaction. The deal instantly transformed the firm into a dominant U.S. royalty platform, driving fiscal 2027 first-quarter revenue to an impressive USD 51 million and sending net income up over 1,500%.

Meanwhile, on the tech and services front, LZ Technology Holdings (LZMH.US) is taking a different route. Despite reporting a solid 37% revenue jump to USD 161.4 million for fiscal 2025, the digital media and smart community platform implemented a 1-for-20 reverse stock split in May 2026 to manage its equity structure.

Here is what else is happening across the market:

  • Chanson International Holding (CHSN.US): The bakery chain returned to profitability in the first half of 2026 with USD 800,000 in net income. To shore up its market position, Chanson executed a 100-for-1 reverse split in May while simultaneously announcing an ambitious AI-driven smart manufacturing strategy.
  • EZGO Technologies (EZGO.US): The short-distance transportation firm saw a massive 2,600% surge in battery pack sales, pushing its recent half-year revenue up 66%. Yet, it is still battling to stay listed, following up a reverse split with a USD 12 million private placement in January 2026.
  • Traws Pharma (TRAW.US): The clinical-stage biopharma is heavily retooling. After pushing back its Phase 2a influenza study, the company secured a USD 60 million PIPE financing in April 2026 to extend its cash runway.
  • ESeen International (ESYN.US): The company remains completely quiet on the news front, with no major operational updates or financial filings surfacing in the recent cycle.

Login to unlock1,282characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

LZ Tech - B

LZ Tech - B

USLZMH

+0.84%

Chanson

Chanson

USCHSN

+0.93%

EZGO Tech

EZGO Tech

USEZGO

-0.35%